Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma A/S (ASND)
:ASND
ASND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$111.09 - $161.00
Previous CloseN/A
Volume129.18K
Average Volume (3M)514.56K
Market Cap
$8.74B
Enterprise Value$8.77B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 21, 2025EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.13
Shares Outstanding60,689,487
10 Day Avg. Volume666,306
30 Day Avg. Volume514,558
Standard Deviation0.11
R-Squared0.09
Alpha-0.00158
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)31.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$198.50Price Target Upside27.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyQuality of life improvement provides the strongest evidence for Yorvipath’s efficacy, with high compliance observed in clinical studies.
Market DemandA significant increase in U.S. Yorvipath prescriptions suggests a rapid uptake since launch announcement.
Bears Say
Safety ConcernsConcerns were expressed about the small molecule approach in hypoparathyroidism treatments, citing a precedent of liver-related side effects observed in other small molecule PTH1R agonists.
---
Ownership Overview
―
Insiders
31.86% Mutual Funds
0.22% Other Institutional Investors
66.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASND FAQ
What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $111.09 and its highest was $161.00 in the past 12 months.
What is Ascendis Pharma A/S’s market cap?
Ascendis Pharma A/S’s market cap is $8.74B.
When is Ascendis Pharma A/S’s upcoming earnings report date?
Ascendis Pharma A/S’s upcoming earnings report date is May 21, 2025 which is in 91 days.
How were Ascendis Pharma A/S’s earnings last quarter?
Ascendis Pharma A/S released its earnings results on Feb 12, 2025. The company reported -$0.669 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.356.
Is Ascendis Pharma A/S overvalued?
According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued.
Does Ascendis Pharma A/S pay dividends?
Ascendis Pharma A/S does not currently pay dividends.
What is Ascendis Pharma A/S’s EPS estimate?
Ascendis Pharma A/S’s EPS estimate is -1.46.
How many shares outstanding does Ascendis Pharma A/S have?
Ascendis Pharma A/S has 60,689,487 shares outstanding.
What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
Ascendis Pharma A/S reported an EPS of -$0.669 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went up 12.962%.
Which hedge fund is a major shareholder of Ascendis Pharma A/S?
Currently, no hedge funds are holding shares in ASND
---
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$198.50 (27.09% Upside)
$198.50 (27.09% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.12%
12-Months-Change
Fundamentals
Return on Equity
330.44%
Trailing 12-Months
Asset Growth
33.92%
Trailing 12-Months
Company Description
Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial growth and successful product launches, particularly with YORVIPATH in the U.S., and promising developments in the pipeline. However, challenges remain with revenue fluctuations for SKYTROFA and market penetration hurdles for YORVIPATH.Read More>---
ASND Stock 12 Month Forecast
Average Price Target
$198.50
▲(27.09% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+19.38%
reiterated a buy rating 7 days ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +19.38% per trade.
---